Sökning: onr:"swepub:oai:DiVA.org:uu-147270" >
Phase II trial of z...
Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma
-
d'Amore, Francesco (författare)
-
Radford, John (författare)
-
- Relander, Thomas (författare)
- Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine
-
visa fler...
-
- Jerkeman, Mats (författare)
- Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine
-
Tilly, Herve (författare)
-
- Österborg, Anders (författare)
- Karolinska Institutet
-
Morschhauser, Franck (författare)
-
Gramatzki, Martin (författare)
-
Dreyling, Martin (författare)
-
Bang, Bo (författare)
-
- Hagberg, Hans (författare)
- Uppsala universitet,Enheten för onkologi
-
visa färre...
-
(creator_code:org_t)
- 2010-08-18
- 2010
- Engelska.
-
Ingår i: British Journal of Haematology. - : Wiley. - 0007-1048 .- 1365-2141. ; 150:5, s. 565-573
- Relaterad länk:
-
https://onlinelibrar...
-
visa fler...
-
http://dx.doi.org/10...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://lup.lub.lu.s...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- The efficacy and safety of zanolimumab (HuMax-CD4) in patients with relapsed or refractory peripheral T Cell lymphoma (PTCL) was evaluated. Twenty-one adult patients with relapsed or refractory CD4+ PTCL of non-cutaneous type (angioimmunoblastic T cell lymphoma (AITL) n = 9, PTCL-not otherwise specified (NOS) n = 7, anaplastic large cell lymphoma (ALCL) n = 4 and enteropathy type T cell lymphoma n = 1) were treated in a single-arm multi-centre study, with weekly intravenous infusions of zanolimumab 980 mg for 12 weeks. Median age was 69 years (range 26-85). Seventeen of the patients had advanced stage disease (Ann Arbor stages III-IV). Objective tumour responses were obtained in 24% of the patients with two complete responses unconfirmed (CRu) and three partial responses (PR). One of the CRus lasted more than 252 d. Responses were obtained in different PTCL entities: AITL (n = 3), ALCL (n = 1) and PTCL-NOS (n = 1). In general, the trial drug was well tolerated with no major toxicity. Zanolimumab at a dose of 980 mg weekly demonstrated clinical activity and an acceptable safety profile in this poor-prognosis patient population, suggesting that the potential benefit combining zanolimumab with standard chemotherapy in the treatment of PTCL should be investigated.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Nyckelord
- peripheral T cell lymphoma
- CD4
- angioimmunoblastic
- anaplastic
- zanolimumab
- MEDICINE
- MEDICIN
- angioimmunoblastic
- peripheral T cell lymphoma
- CD4
- zanolimumab
- anaplastic
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
d'Amore, Frances ...
-
Radford, John
-
Relander, Thomas
-
Jerkeman, Mats
-
Tilly, Herve
-
Österborg, Ander ...
-
visa fler...
-
Morschhauser, Fr ...
-
Gramatzki, Marti ...
-
Dreyling, Martin
-
Bang, Bo
-
Hagberg, Hans
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Hematologi
- Artiklar i publikationen
-
British Journal ...
- Av lärosätet
-
Uppsala universitet
-
Lunds universitet
-
Karolinska Institutet